Final Analysis Caps Merck’s COVID-19 Antiviral Pill at 30% Efficacy
Last Friday, Merck released a final analysis of its clinical trial for molnupiravir, their COVID-19 antiviral pill. An interim analysis stated molnupiravir reduced the risk of hospitalization and death by 50%; it has now been lowered to 30%.
Read More »